Macrocure (NASDAQ: MCUR) and AbbVie (NYSE:ABBV) are both healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, risk, analyst recommendations, valuation, institutional ownership, dividends and profitability.

Analyst Ratings

This is a breakdown of recent recommendations for Macrocure and AbbVie, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Macrocure 0 0 0 0 N/A
AbbVie 0 7 9 0 2.56

AbbVie has a consensus price target of $90.67, suggesting a potential upside of 1.08%. Given AbbVie’s higher possible upside, analysts plainly believe AbbVie is more favorable than Macrocure.

Risk and Volatility

Macrocure has a beta of 0.62, suggesting that its stock price is 38% less volatile than the S&P 500. Comparatively, AbbVie has a beta of 1.51, suggesting that its stock price is 51% more volatile than the S&P 500.

Valuation and Earnings

This table compares Macrocure and AbbVie’s top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio EBITDA Earnings Per Share Price/Earnings Ratio
Macrocure N/A N/A N/A ($1.91) -0.79
AbbVie $26.71 billion 5.35 $11.57 billion $4.07 22.04

AbbVie has higher revenue and earnings than Macrocure. Macrocure is trading at a lower price-to-earnings ratio than AbbVie, indicating that it is currently the more affordable of the two stocks.

Dividends

AbbVie pays an annual dividend of $2.56 per share and has a dividend yield of 2.9%. Macrocure does not pay a dividend. AbbVie pays out 62.9% of its earnings in the form of a dividend. AbbVie has raised its dividend for 44 consecutive years.

Profitability

This table compares Macrocure and AbbVie’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Macrocure N/A -24.50% -22.85%
AbbVie 24.77% 150.27% 12.52%

Insider and Institutional Ownership

2.8% of Macrocure shares are held by institutional investors. Comparatively, 68.3% of AbbVie shares are held by institutional investors. 0.2% of AbbVie shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

AbbVie beats Macrocure on 12 of the 13 factors compared between the two stocks.

Macrocure Company Profile

Leap Therapeutics Ltd, formerly Macrocure Ltd, is a biotechnology company. The Company is focused on developing, manufacturing and commercializing cell therapy products to address unmet needs for the treatment of chronic wounds, such as diabetic foot ulcers (DFUs) and venous leg ulcers (VLUs). Its product candidate, CureXcell, is a combination of living human white blood cells that have been activated to facilitate the healing process and stimulate wound closure. CureXcell is in Phase III. Its CureXcell addresses each phase of healing in the impaired wound, including the production of growth factors and other biochemical factors involved in fibroblast activation, cell migration and extracellular matrix production, stimulating the body’s natural healing process. Its delivery method of direct superficial injection into the chronic wound allows the precise delivery of the cells into the defective wound tissue where they can be effective.

AbbVie Company Profile

AbbVie Inc. (AbbVie) is a research-based biopharmaceutical company. The Company is engaged in the discovery, development, manufacture and sale of a range of pharmaceutical products. Its products are focused on treating conditions, such as chronic autoimmune diseases in rheumatology, gastroenterology and dermatology; oncology, including blood cancers; virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV); neurological disorders, such as Parkinson’s disease and multiple sclerosis; metabolic diseases, including thyroid disease and complications associated with cystic fibrosis, and other serious health conditions. It offers products in various categories, including HUMIRA (adalimumab), Oncology products, Virology Products, Additional Virology products, Metabolics/Hormones products, Endocrinology products and other products, which include Duopa and Duodopa (carbidopa and levodopa), Anesthesia products and ZINBRYTA (daclizumab).

Receive News & Stock Ratings for Macrocure Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Macrocure Ltd and related stocks with our FREE daily email newsletter.